10x Genomics faces a decelerating revenue trajectory, with 2026Q2 revenue down 12.6% year-over-year to $151.0M, and persistent operating losses averaging around $20M per quarter.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.15+43.8% vs -$0.27 | $151M+1.8% vs $148M |
Q3 2026 Aug 6, 2026 | -$0.14+42.4% vs -$0.24 | $151M+3.0% vs $147M |
Q2 2026 May 7, 2026 | -$0.10+65.5% vs -$0.29 | $151M+3.0% vs $146M |
Q1 2026 Feb 12, 2026 | -$0.13+31.6% vs -$0.19 | $166M+4.0% vs $160M |
TXG launches Sentira Single Cell, a Claude-powered AI tool to simplify complex data analysis, accelerate research and unlock recurring revenue potential.
10x Genomics raises its 2026 revenue outlook on strong Atera demand and spatial consumables growth, but production constraints and margin pressure remain challenges.
10x Genomics NASDAQ: TXG raised its full-year revenue outlook after reporting modest third-quarter growth and increased its shipment target for its new Atera spatial biology platform.
Small-cap stocks have benefited from a range of tailwinds this year.
Benchmark TXG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for 10x Genomics, Inc. (TXG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $59.28 | $7.53B | -115.60 | 5.25% | -10.84% | -8.19% | — | |
| $2.26 | $701.96M | -5.36 | 3.89% | -81.31% | -2618.51% | — | |
| $213.13 | $32.25B | 36.67 | -0.78% | 19.72% | 31.45% | — | |
| $61.31 | $9.33B | -75.77 | 2.08% | -3.51% | -5.05% | 0.24% | |
| $23.74 | $674.23M | -7.22 | 13.83% | -27.53% | -8.8% | — | |
| $78.56 | $4.06B | 33.58 | 13.79% | 25.86% | 34.08% | — |
10x Genomics, Inc. (TXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
10x Genomics, Inc. (TXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 8, 2026·SEC
May 7, 2026·SEC
Get notified when TXG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
10x Genomics, Inc. (TXG) stock FAQ — growth, dividends, profitability & financials explained
10x Genomics, Inc. (TXG) reported $618.6M in revenue over the trailing twelve months. Revenue was $642.8M in fiscal year 2025. That is 804% more than the $71.1M of fiscal year 2017.
10x Genomics, Inc. (TXG) revenue fell by 3.6% over the trailing twelve months, compared with the twelve months before.
No. 10x Genomics, Inc. (TXG) reported a net loss of $67.1M over the trailing twelve months.
10x Genomics, Inc. (TXG) had a return on equity (ROE) of -8.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
10x Genomics, Inc. (TXG) generated $93.8M in free cash flow over the trailing twelve months.
